Regeneron Pharmaceuticals, Inc. (REGN) Financial Statements
Regeneron Pharmaceuticals financial statements at a glance
Regeneron Pharmaceuticals reported revenue of $14.34 billion for fiscal year 2025 (ended December 31, 2025), up 1.0% from fiscal year 2024. Net income was $4.50 billion, a net margin of 31.4%.
At the end of fiscal year 2025 it had total assets of $40.56 billion, total liabilities of $9.30 billion and shareholders' equity of $31.26 billion, with total debt of $2.71 billion.
Its operations brought in $4.98 billion of cash.
The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.
Figures from company filings, in USD; latest fiscal year ended December 31, 2025.
Regeneron Pharmaceuticals, Inc.
Income Statement
Annual • USD
Regeneron Pharmaceuticals key figures by fiscal year
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $14.3B | $14.2B | $13.1B | $12.2B | $16.1B |
| Gross profit | $12.4B | $12.4B | $11.4B | $10.9B | $13.6B |
| Operating income | $3.6B | $4.0B | $4.0B | $4.7B | $8.9B |
| Net income | $4.5B | $4.4B | $4.0B | $4.3B | $8.1B |
| Diluted EPS | – | – | – | – | $71.97 |
| Total assets | $40.6B | $37.8B | $33.1B | $29.2B | $25.4B |
| Total liabilities | $9.3B | $8.4B | $7.1B | $6.6B | $6.7B |
| Shareholders' equity | $31.3B | $29.4B | $26.0B | $22.7B | $18.8B |
| Cash | – | – | – | – | $2.9B |
| Total debt | $2.7B | $2.7B | $2.7B | $2.7B | $2.7B |
| Operating cash flow | $5.0B | $4.4B | $4.6B | $5.0B | $7.1B |
| Capital spending | – | – | – | – | $551.9M |
| Free cash flow | – | – | – | – | $6.5B |
In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2020.
Questions and answers
What was Regeneron Pharmaceuticals's revenue in fiscal year 2025?
$14.34 billion, up 1.0% from $14.20 billion in fiscal year 2024.
How much profit does Regeneron Pharmaceuticals make?
Regeneron Pharmaceuticals reported net income of $4.50 billion for fiscal year 2025 (31.4% of revenue); operating income was $3.58 billion.
How much cash and debt does Regeneron Pharmaceuticals have?
At the end of fiscal year 2025: total debt of $2.71 billion.
